Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells + IL-15 With/Without Ipilimumab or Cetuximab in Advanced Head & Neck Cancer
NCT04290546Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2020
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytokine-induced memory-like natural killer cells and nogapendekin alfa inbakicept in squamous cell carcinoma of the head and neck (HNSCC) and salivary gland carcinoma (SGC) (3 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 100 days. Started Jul 2020; status: completed.
02
Drugs
cytokine-induced memory-like natural killer cellsnogapendekin alfa inbakicept
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT04290546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290546.